|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
124,070,000 |
Market
Cap: |
88.14(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.5599 - $5.72 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Seres Therapeutics is a microbiome therapeutics platform company developing live biotherapeutic drugs. SER-109, Co.'s lead clinical candidate is an oral, purified bacterial spore-based microbiome therapeutic candidate consisting of a consortium of purified Firmicutes spores. Using Co.'s microbiome therapeutics platform, Co. is also developing SER-287 and SER-301 to treat ulcerative colitis. Co. evaluates microbiome pharmacokinetic and pharmacodynamic data from across its clinical and pre-clinical portfolios using its reverse translation microbiome therapeutics capabilities to conduct research on various indications, including inflammatory and immune diseases, cancer, and metabolic diseases.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
8,738,243 |
Total Buy Value |
$0 |
$0 |
$0 |
$27,525,465 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
6,901 |
43,282 |
78,051 |
90,101 |
Total Sell Value |
$6,488 |
$45,780 |
$92,717 |
$168,989 |
Total People Sold |
6 |
7 |
8 |
8 |
Total Sell Transactions |
6 |
13 |
21 |
23 |
End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Desrosier Thomas |
Chief Legal Officer and EVP |
|
2024-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,625 |
124,516 |
|
- |
|
Young Teresa L. |
See Remarks |
|
2023-10-30 |
4 |
AS |
$1.35 |
$3,924 |
D/D |
(2,907) |
8,454 |
|
-41% |
|
Henn Matthew R. |
See Remarks |
|
2023-10-30 |
4 |
AS |
$1.35 |
$5,246 |
D/D |
(3,886) |
56,356 |
|
-41% |
|
Arkowitz David |
Chief Financial Officer |
|
2023-10-30 |
4 |
AS |
$1.35 |
$5,489 |
D/D |
(4,066) |
175,756 |
|
-41% |
|
Desrosier Thomas |
Chief Legal Officer and EVP |
|
2023-10-30 |
4 |
AS |
$1.35 |
$5,611 |
D/D |
(4,156) |
113,891 |
|
-41% |
|
Ege David S. |
See Remarks |
|
2023-10-30 |
4 |
AS |
$1.35 |
$5,489 |
D/D |
(4,066) |
66,991 |
|
-41% |
|
Cloghessy Paula |
See Remarks |
|
2023-10-30 |
4 |
AS |
$1.35 |
$3,920 |
D/D |
(2,904) |
45,684 |
|
-41% |
|
Shaff Eric D. |
CEO and President |
|
2023-10-30 |
4 |
AS |
$1.35 |
$11,545 |
D/D |
(8,552) |
115,620 |
|
-41% |
|
Von Moltke Lisa |
See Remarks |
|
2023-10-30 |
4 |
AS |
$1.35 |
$5,713 |
D/D |
(4,232) |
9,513 |
|
-41% |
|
Young Teresa L. |
See Remarks |
|
2023-10-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,361 |
11,361 |
|
- |
|
Henn Matthew R. |
See Remarks |
|
2023-10-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,623 |
60,242 |
|
- |
|
Arkowitz David |
Chief Financial Officer |
|
2023-10-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,209 |
179,822 |
|
- |
|
Desrosier Thomas |
Chief Legal Officer and EVP |
|
2023-10-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,501 |
118,047 |
|
- |
|
Ege David S. |
See Remarks |
|
2023-10-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,361 |
71,057 |
|
- |
|
Cloghessy Paula |
See Remarks |
|
2023-10-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,418 |
48,588 |
|
- |
|
Shaff Eric D. |
CEO and President |
|
2023-10-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
27,838 |
124,172 |
|
- |
|
Von Moltke Lisa |
See Remarks |
|
2023-10-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,745 |
13,745 |
|
- |
|
Ege David S. |
See Remarks |
|
2023-04-28 |
4 |
AS |
$5.19 |
$36,527 |
D/D |
(7,038) |
59,696 |
|
-34% |
|
Arkowitz David |
Chief Financial Officer |
|
2023-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
42,500 |
166,613 |
|
- |
|
Ege David S. |
See Remarks |
|
2023-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
66,734 |
|
- |
|
Ege David S. |
See Remarks |
|
2022-10-31 |
4 |
AS |
$7.93 |
$39,745 |
D/D |
(5,012) |
46,734 |
|
-37% |
|
Arkowitz David |
Chief Financial Officer |
|
2022-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
42,500 |
112,992 |
|
- |
|
Ege David S. |
See Remarks |
|
2022-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
51,746 |
|
- |
|
Flagship Pioneering Fund Vii, L.p. |
10% Owner |
|
2022-07-05 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,825,495 |
|
87% |
|
Afeyan Noubar |
10% Owner |
|
2022-07-05 |
4 |
B |
$3.15 |
$27,525,465 |
I/I |
8,738,243 |
5,825,495 |
1.5 |
87% |
|
207 Records found
|
|
Page 2 of 9 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|